about
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis.Treating ALK-positive non-small cell lung cancer.Prognostic factors for multiple myeloma in the era of novel therapiesA new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic optionsConsolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonatesCombination of conventional culture, vial culture, and broad-range PCR of sonication fluid for the diagnosis of prosthetic joint infectionPrimary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasoneVulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patientsEfficacy of lenalidomide as salvage therapy for patients with AL amyloidosisElevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMImmunotherapy for pancreatic cancer: A 2020 updateBone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk groupPrognosis and Management of BRAF V600E-Mutated Pregnancy-Associated MelanomaImpact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasonePulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcomeIdentifying the optimum first-line therapy in BRAF-mutant metastatic melanomaImpact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline TherapyReactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
P50
Q49546522-106ED817-8EAF-4321-98F7-2061837B823AQ54967334-23FB20E3-89BF-4CFA-8D30-B45E8567C3B1Q58552721-5B83F1DB-EF9B-474B-88D7-27875DC10643Q61445851-B8A26E1A-D331-4FA3-A972-9CD874989DE3Q90787473-DDEE47B7-705E-4092-A90D-DFDC240BC828Q90902462-8F9B4F8E-3F26-4D67-9F9D-53028EFF2C7BQ90925215-05DEAF9A-009D-43F6-815E-2E3224C83755Q90978221-FB4BCB42-BE30-428C-8F46-1C7E8567439EQ91136241-A89FF7E2-AA5D-4127-A650-6E7138862475Q91492419-8CC7E5C6-49E5-4461-AFA6-0D9BF90DFEDAQ91569750-7AFF7DAB-DDA9-419F-BB23-4AD6233D4D86Q91658209-D87E4AAB-6F0F-4D46-8F38-0E884E0A1C51Q91760053-F4854CF2-8878-47AD-87CD-127A7E190EFFQ91844274-C33DFD34-732C-4692-AE00-32E8FEDE0124Q92135856-4A2A1F4D-0971-4FED-B311-FC7FEA40D324Q92429568-9DC7894A-E72B-4B99-BECE-26873E57E369Q92903027-95EFF3B5-16A0-479D-8021-9D8F4C92D414Q93103947-BFDB65F6-712E-4129-A22B-31C723A58A8C
P50
description
researcher (ORCID 0000-0003-2620-4004)
@en
name
Dimitrios C Ziogas
@en
type
label
Dimitrios C Ziogas
@en
prefLabel
Dimitrios C Ziogas
@en
P31
P496
0000-0003-2620-4004